Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Paolieri F"" wg kryterium: Wszystkie pola


Tytuł :
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study).
Autorzy :
Rebuzzi SE; Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino of Genova, Largo Rosanna Benzi 10, Genova, 16132, Italy.
Signori A; Department of Health Sciences, Section of Biostatistics, University of Genova, Genova, Italy.
Banna GL; Department of Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK Cannizzaro Hospital, Catania, Italy.
Maruzzo M; Medical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy.
De Giorgi U; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy.
Pedrazzoli P; Medical Oncology Unit, IRCCS Policlinico San Matteo, Pavia, Italy.
Sbrana A; Medical Oncology Unit 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.
Zucali PA; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy.
Masini C; Medical Oncology Unit, AUSL-IRCCS of Reggio Emilia, Reggio Emilia, Italy.
Naglieri E; Division of Medical Oncology, IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
Procopio G; SS Oncologia Medica Genitourinaria, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Merler S; Department of Oncology, Azienda Ospedaliera Universitaria Integrata di Verona, University of Verona,Verona, Italy.
Tomasello L; Academic Unit of Medical Oncology, IRCCS Ospedale Policlinico San Martino of Genova, Genova, Italy.
Fratino L; Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano CRO-IRCCS, Aviano, Italy.
Baldessari C; Medical Oncology Unit, Department of Oncology and Hemathology, University Hospital of Modena, Modena, Italy.
Ricotta R; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano, Italy.
Panni S; Medical Oncology Unit, ASST - Istituti Ospitalieri Cremona Hospital, Cremona, Italy.
Mollica V; Oncologia Medica, Azienda Ospedaliero-Universitaria of Bologna, Bologna, Italy.
Sorarù M; U.O. Oncologia, Ospedale di Camposampiero, Italy.
Santoni M; Oncology Unit, Macerata Hospital, Macerata, Italy.
Cortellini A; Department of Biotechnology and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Prati V; Medical Oncology Unit, ASL CN 2, Alba-Bra, Italy.
Soto Parra HJ; Department of Oncology, Medical Oncology, University Hospital Policlinico-San Marco, Catania, Italy.
Stellato M; Department of Medical Oncology, Università Campus Bio-Medico of Roma, Rome, Italy.
Atzori F; Medical Oncology Department, University Hospital, University of Cagliari, Cagliari, Italy.
Pignata S; Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.
Messina C; Medical Oncology Department, Santa Chiara Hospital, Trento, Italy.
Messina M; UOC Oncologia Medica, Istituto Fondazione G. Giglio, Cefalù, Italy.
Morelli F; Medical Oncology Department, Casa Sollievo Della Sofferenza Hospital, IRCCS, San Giovanni Rotondo, Italy.
Prati G; Department of oncology and advanced technologies AUSL - IRCCS Reggio Emilia, Reggio Emilia, Italy.
Nolè F; Medical Oncology Division of Urogenital & Head & Neck Tumors, IEO, European Institute of Oncology IRCCS, Milano, Italy.
Vignani F; Division of Medical Oncology, Ordine Mauriziano Hospital, Torino, Italy.
Cavo A; Oncology Unit, Villa Scassi Hospital, Genova, Italy.
Roviello G; Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Firenze, Firenze, Italy.
Pierantoni F; Medical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy.
Casadei C; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy.
Bersanelli M; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
Chiellino S; Medical Oncology Unit, IRCCS Policlinico San Matteo, Pavia, Italy.
Paolieri F; Medical Oncology Unit 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.
Perrino M; Department of Oncology, IRCCS, Humanitas Clinical and Research Center, Rozzano, Milano, Italy.
Brunelli M; Department of Diagnostics and Public Health, Pathology Unit, University and Hospital Trust of Verona, Verona, Italy.
Iacovelli R; Medical Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Porta C; Chair of Oncology, Department of Biomedical Sciences and Human Oncology, University of Bari 'A. Moro', Bari, Italy.
Buti S; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
Fornarini G; Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino of Genova, Genova, Italy.
Pokaż więcej
Źródło :
Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2021 May 18; Vol. 13, pp. 17588359211019642. Date of Electronic Publication: 2021 May 18 (Print Publication: 2021).
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone.
Autorzy :
Crucitta S; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University Hospital of Pisa, 55, Via Roma, 56126, Pisa, Italy.
Del Re M; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University Hospital of Pisa, 55, Via Roma, 56126, Pisa, Italy. .
Paolieri F; Unit of Medical Oncology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Bloise F; Unit of Medical Oncology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Sbrana A; Unit of Medical Oncology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Sammarco E; Unit of Medical Oncology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Mercinelli C; Unit of Medical Oncology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Cucchiara F; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University Hospital of Pisa, 55, Via Roma, 56126, Pisa, Italy.
Fontanelli L; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University Hospital of Pisa, 55, Via Roma, 56126, Pisa, Italy.
Galli L; Unit of Medical Oncology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Danesi R; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University Hospital of Pisa, 55, Via Roma, 56126, Pisa, Italy.
Pokaż więcej
Źródło :
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2020 Oct; Vol. 86 (4), pp. 527-533. Date of Electronic Publication: 2020 Sep 18.
Typ publikacji :
Journal Article
MeSH Terms :
Abiraterone Acetate/*pharmacology
Adenocarcinoma/*drug therapy
Biomarkers, Tumor/*genetics
Drug Resistance, Neoplasm/*genetics
Prostatic Neoplasms, Castration-Resistant/*drug therapy
Steroid 17-alpha-Hydroxylase/*genetics
Abiraterone Acetate/therapeutic use ; Adenocarcinoma/blood ; Adenocarcinoma/genetics ; Adenocarcinoma/mortality ; Aged ; Aged, 80 and over ; Disease Progression ; Humans ; Kallikreins/blood ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoplasm Grading ; Polymorphism, Single Nucleotide ; Prognosis ; Progression-Free Survival ; Prostate/pathology ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms, Castration-Resistant/blood ; Prostatic Neoplasms, Castration-Resistant/genetics ; Prostatic Neoplasms, Castration-Resistant/mortality ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Clinical and economic effect of administration of red blood product transfusions in an outpatient supportive care cancer service.
Autorzy :
Sbrana A; Medical Oncology Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, I-56126 Pisa, Italy.
Paolieri F; Medical Oncology Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, I-56126 Pisa, Italy.
Bloise F; Medical Oncology Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, I-56126 Pisa, Italy.
Danova M; Internal Medicine and Medical Oncology, AZIENDA Socio-Sanitaria Territoriale di Pavia, I-27100 Pavia, Italy.
Galli L; Medical Oncology Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, I-56126 Pisa, Italy.
Brunetti IM; Medical Oncology Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, I-56126 Pisa, Italy.
Vasile E; Medical Oncology Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, I-56126 Pisa, Italy.
Ricci S; Medical Oncology Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, I-56126 Pisa, Italy.
Falcone A; Medical Oncology Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, I-56126 Pisa, Italy.
Antonuzzo A; Medical Oncology Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, I-56126 Pisa, Italy.
Pokaż więcej
Źródło :
Biomedical reports [Biomed Rep] 2020 Apr; Vol. 12 (4), pp. 199-203. Date of Electronic Publication: 2020 Feb 10.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Effectiveness of Multi-Prognostic Index in older patients with advanced malignancies treated with immunotherapy.
Autorzy :
Sbrana A; Oncology Unit 1, Pisa University Hospital, via Roma 67, 56126 Pisa, Italy.
Antognoli R; Geriatrics Unit, Department of Clinical & Experimental Medicine, University of Pisa, via Savi 10, 56127 Pisa, Italy.
Pasqualetti G; Geriatrics Unit, Department of Clinical & Experimental Medicine, University of Pisa, via Savi 10, 56127 Pisa, Italy. Electronic address: .
Linsalata G; Geriatrics Unit, Department of Clinical & Experimental Medicine, University of Pisa, via Savi 10, 56127 Pisa, Italy.
Okoye C; Geriatrics Unit, Department of Clinical & Experimental Medicine, University of Pisa, via Savi 10, 56127 Pisa, Italy.
Calsolaro V; Geriatrics Unit, Department of Clinical & Experimental Medicine, University of Pisa, via Savi 10, 56127 Pisa, Italy.
Paolieri F; Oncology Unit 1, Pisa University Hospital, via Roma 67, 56126 Pisa, Italy.
Bloise F; Oncology Unit 1, Pisa University Hospital, via Roma 67, 56126 Pisa, Italy.
Ricci S; Oncology Unit 1, Pisa University Hospital, via Roma 67, 56126 Pisa, Italy.
Antonuzzo A; Oncology Unit 1, Pisa University Hospital, via Roma 67, 56126 Pisa, Italy. Electronic address: .
Monzani F; Geriatrics Unit, Department of Clinical & Experimental Medicine, University of Pisa, via Savi 10, 56127 Pisa, Italy.
Pokaż więcej
Źródło :
Journal of geriatric oncology [J Geriatr Oncol] 2020 Apr; Vol. 11 (3), pp. 503-507. Date of Electronic Publication: 2019 Oct 28.
Typ publikacji :
Journal Article
MeSH Terms :
Carcinoma, Non-Small-Cell Lung*/therapy
Immunotherapy*
Lung Neoplasms*
Aged ; Aged, 80 and over ; Female ; Geriatric Assessment ; Humans ; Male ; Prognosis
Czasopismo naukowe
Tytuł :
Dedifferentiated liposarcoma: when eribulin can make the difference.
Autorzy :
Sbrana A; Medical Oncology Unit 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.; Department of Translational Research & New Technologies in Medicine & Surgery, University of Pisa, Pisa, Italy.
Paolieri F; Medical Oncology Unit 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.; Department of Translational Research & New Technologies in Medicine & Surgery, University of Pisa, Pisa, Italy.
Bloise F; Medical Oncology Unit 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.; Department of Translational Research & New Technologies in Medicine & Surgery, University of Pisa, Pisa, Italy.
Manacorda S; Medical Oncology Unit 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.; Department of Translational Research & New Technologies in Medicine & Surgery, University of Pisa, Pisa, Italy.
Nuzzo A; Medical Oncology Unit 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.; Department of Translational Research & New Technologies in Medicine & Surgery, University of Pisa, Pisa, Italy.
Sammarco E; Medical Oncology Unit 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.; Department of Translational Research & New Technologies in Medicine & Surgery, University of Pisa, Pisa, Italy.
Galli L; Medical Oncology Unit 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.; Department of Translational Research & New Technologies in Medicine & Surgery, University of Pisa, Pisa, Italy.
Falcone A; Medical Oncology Unit 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.; Department of Translational Research & New Technologies in Medicine & Surgery, University of Pisa, Pisa, Italy.
Pokaż więcej
Źródło :
Future oncology (London, England) [Future Oncol] 2020 Jan; Vol. 16 (1s), pp. 21-24. Date of Electronic Publication: 2019 Dec 24.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Furans/*therapeutic use
Ketones/*therapeutic use
Liposarcoma/*diagnosis
Liposarcoma/*drug therapy
Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Disease Progression ; Fatal Outcome ; Furans/administration & dosage ; Furans/adverse effects ; Humans ; Ketones/administration & dosage ; Ketones/adverse effects ; Male ; Retreatment ; Tomography, X-Ray Computed ; Treatment Outcome
Czasopismo naukowe
Tytuł :
AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer.
Autorzy :
Del Re M; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Crucitta S; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Sbrana A; Medical Oncology Unit, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
Rofi E; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Paolieri F; Medical Oncology Unit, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
Gianfilippo G; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Galli L; Medical Oncology Unit, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
Falcone A; Medical Oncology Unit, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
Morganti R; Section of Statistics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Porta C; Department of Internal Medicine, University of Pavia, Pavia, Italy.; Division of Translational Oncology, I.R.C.C.S. Istituti Clinici Scientifici Maugeri, Pavia, Italy.
Efstathiou E; Division of Cancer Medicine, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
van Schaik R; Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands.
Jenster G; Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Danesi R; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Pokaż więcej
Źródło :
BJU international [BJU Int] 2019 May 04. Date of Electronic Publication: 2019 May 04.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
A case of a patient with severe renal failure on hemodialysis treated with vismodegib for relapsing basal cell carcinoma.
Autorzy :
Sbrana A; 1 U.O. Oncologia Medica 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Antonuzzo A; 2 U.O. Oncologia Medica 1, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Galli L; 1 U.O. Oncologia Medica 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Biasco E; 1 U.O. Oncologia Medica 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Musettini G; 1 U.O. Oncologia Medica 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Paolieri F; 1 U.O. Oncologia Medica 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Ricci S; 2 U.O. Oncologia Medica 1, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Pokaż więcej
Źródło :
Tumori [Tumori] 2018 Dec; Vol. 104 (6), pp. NP2-NP4. Date of Electronic Publication: 2018 Jun 13.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Anilides/*therapeutic use
Carcinoma, Basal Cell/*drug therapy
Neoplasm Recurrence, Local/*drug therapy
Pyridines/*therapeutic use
Aged, 80 and over ; Humans ; Male ; Renal Dialysis/methods ; Renal Insufficiency
Czasopismo naukowe
Tytuł :
Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience.
Autorzy :
Sbrana A; U.O. Oncologia Medica 2 Universitaria, Polo Oncologico, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy .
Biasco E; DH Oncologico Portoferraio, Azienda Toscana Nord Ovest, Livorno, Italy.
Paolieri F; U.O. Oncologia Medica 2 Universitaria, Polo Oncologico, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Palesandro E; Istituto di Candiolo - IRCCS, Turin, Italy.
Caserta C; S. C. Oncologia Medica, Azienda Ospedaliera S. Maria, Terni, Italy.
Iacovelli R; U.O.C. Oncologia Medica, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
Detti B; U.O. Radioterapia, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Santini D; U.O.S. Day Hospital di Oncologia, Università Campus Biomedico, Rome, Italy.
Mosca A; S.C. Oncologia Medica, Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara, Italy.
Morelli F; U.O.C. Oncologia, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
Fornarini G; U.O. Oncologia Medica 1, Policlinico San Martino, Genoa, Italy.
De Giorgi U; U.O. Oncologia Medica, IRST, Meldola, Italy.
Masini C; U.O. Oncologia Medica, Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Italy.
Galli L; U.O. Oncologia Medica 2 Universitaria, Polo Oncologico, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2018 Aug; Vol. 38 (8), pp. 4913-4918.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Angiogenesis Inhibitors/*therapeutic use
Carcinoma, Renal Cell/*drug therapy
Kidney Neoplasms/*drug therapy
Pyrimidines/*therapeutic use
Receptors, Vascular Endothelial Growth Factor/*antagonists & inhibitors
Sulfonamides/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Disease-Free Survival ; Female ; Humans ; Italy ; Male ; Middle Aged ; Retrospective Studies
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies